R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in U.S. for the Treatment of Severe Dry Eye

Published: May 20, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TOKYO--(BUSINESS WIRE)--R-Tech Ueno, Ltd. (JASDAQ:4573): This is to announce start of the patient enrollment of the first stage of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101(Note 1); hereafter RU-101 ophthalmic solution), which is being developed in our company, in US for the treatment of severe dry eye. We are currently developing RU-101 ophthalmic solution to treat severe dry eye for which no effective treatment has been established.

Help employers find you! Check out all the jobs and post your resume.

Back to news